Navigation Links
Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
Date:12/3/2007

SOUTH SAN FRANCISCO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics, today announced the appointment of Lesley A. Stolz, Ph.D., to the position of Vice President, Corporate and Business Development. Dr. Stolz will be responsible for overseeing the company's partnering and collaboration activities, reporting directly to Eric Bjerkholt, Senior Vice President, Corporate Development and Finance.

"We are pleased to welcome Lesley to the Sunesis team. Her proven track record and diverse experience in managing all aspects of partnering, in-licensing, intellectual property transfers and M&A activities will provide valuable insights to all of our strategic business development initiatives," said Daniel Swisher, Chief Executive Officer and President of Sunesis.

Dr. Stolz joins Sunesis with more than a decade of biotechnology industry experience. Most recently, she served as Senior Director, Business Development for Aerovance, Inc. where she led efforts to partner the company's Phase 2 asset for uncontrolled asthma. Dr. Stolz was Senior Director, Business Development for GPC Biotech AG of Germany from 2002 to 2006 where she co-led the acquisition of Axxima Pharmaceuticals. While there, she was also responsible for the discovery, evaluation and execution of GPC Biotech's in-licensing activities and helped to set business development and merger and acquisition strategies. From 2001 to 2002, Dr. Stolz served as Director, Business Development for Cell Genesys, Inc. with responsibility for identifying and negotiating partnerships for the company's cancer therapy research and development programs. Dr. Stolz received her Ph.D. and M.S. degrees from the University of Rochester and a B.S. from the University of Virginia. She conducted postdoctoral research at Harvard Medical School's Department of Biochemistry and Molecular Pharmacology.

Option Award Disclosure

The Compensation Committee of the company's Board of Directors approved an employment commencement inducement grant to Dr. Stolz of a non-qualified stock option to purchase 60,000 shares of Sunesis common stock, effective November 30, 2007. Pursuant to Nasdaq Marketplace Rule 4350 (i)(1)(A)(iv), this option award was granted without shareholder approval under Sunesis' 2006 Employment Commencement Incentive Plan. Nasdaq rules require public announcement of option grants made under this type of plan. The options were granted at an exercise price equal to the fair market value of the company's common stock at the close of the trading day on the grant date. The options have a ten-year term, and, subject to the terms and conditions of the company's 2006 Employment Commencement Incentive Plan, vest over four years as follows: 25 percent of the shares will vest on the one year anniversary of the grant date, and the remaining 75 percent will vest in 36 equal monthly increments during each of the second, third and fourth years thereafter.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... FireflySci has been ... leading laboratories all over the globe. Their cute firefly logo has been spreading ... cuvettes, FireflySci makes spectrophotometer calibration standards that never require recalibration. These revolutionary ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of Investment’s New ... San Francisco. Located at booth number 7301, representatives from the Thai Government, research ... the Thai biotechnology and life sciences sector. , Deputy Secretary General of ...
(Date:5/25/2016)... ... 25, 2016 , ... Founder of the Fitzmaurice Hand Institute ... surgery of the hand by the National Board of Physicians and Surgeons, as ... beyond in his pursuit of providing the most comprehensive, effective treatment for his ...
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the ... research that could lead to one good one. Surviving Mesothelioma has just posted an ... The team evaluated 98 mesothelioma patients who got a second kind of ...
Breaking Biology Technology:
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
Breaking Biology News(10 mins):